Key result
Dapagliflozin reduces worsening heart failure or CV death in patients with HFmrEF or HFpEF.
Why the study?
Does dapagliflozin reduce the combined risk of worsening heart failure or cardiovascular death in patients with heart failure and a mildly reduced or preserved ejection fraction?
Does dapagliflozin reduce the combined risk of worsening heart failure or cardiovascular death in patients with heart failure and a mildly reduced or preserved ejection fraction?
Dapagliflozin reduces the composite risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.
Supports dapagliflozin use in HFmrEF/HFpEF; extends SGLT2 inhibitor benefits across the ejection fraction spectrum.
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
No takes yet. Share an insight, caveat, or question.
Solomon et al. (2022) studied this question. Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death in patients with mildly reduced or preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: